AX-2026-042513
CJC-1295 (no DAC) · 2 mg declared · Hunan Aslsen Technology Co., Ltd. · lot HOMO-2512-D5035
- Report ID
- AX-2026-042513
- Compound
- CJC-1295 (no DAC)
- Compound class
- Growth-hormone axis peptides
- Supplier
- Homopeptide — Hunan Aslsen Technology Co., Ltd.
- Batch / lot
- HOMO-2512-D5035
- Declared label claim
- 2mg
- Laboratory
- Janoshik Analytical
- Assay date
- 15 Feb 2026
- Submitted
- 04 Mar 2026
- Quarter
- 2026-Q1
- Submitter
- ha.tulloch
- Sample provenance
- Laboratory-retained
Results
Measured against the index acceptance specification for the growth-hormone axis peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.
| Parameter | Method | Result | Unit | Index spec | |
|---|---|---|---|---|---|
| Purity | RP-HPLC, 30 min gradient, 214 nm | 99.69 | % area | ≥ 98.0 | PASS |
| Total impurities | RP-HPLC, sum of reported peaks | 0.31 | % area | ≤ 2.0 | PASS |
| Largest single impurity | RP-HPLC — des-Tyr1 (−163 Da) | 0.21 | % area | ≤ 1.00 | PASS |
| Identity — theoretical monoisotopic mass | calculated from molecular formula | 3365.7402 | Da | — | NOT TESTED |
| Identity — observed monoisotopic mass | LC-MS, high resolution (ESI-TOF/QTOF) | 3365.7355 | Da | — | NOT TESTED |
| Mass accuracy | observed vs theoretical | -1.4 | ppm | ± 15 | PASS |
| Total peptide content | by difference from the gravimetric mass balance | 89.55 | %w/w | — | NOT TESTED |
| Target-compound content | total peptide content × purity | 89.27 | %w/w | — | NOT TESTED |
| Gross fill (as weighed) | five-place balance, under nitrogen | 2.15 | mg | 2 mg declared | NOT TESTED |
| Recovered target peptide | gross fill × target content | 1.919 | mg | 2 mg claim | NOT TESTED |
| Recovery against label claim | recovered ÷ claim | 96.0 | % | 90.0 – 110.0 | PASS |
| Water content | Karl Fischer, coulometric, duplicate | 5.68 | % | ≤ 9.0 | PASS |
| Counter-ion (acetate) | anion-exchange ion chromatography | 3.98 | % | ≤ 12.0 | PASS |
| Residual solvent + inorganic residue | estimated — see /methods/residual-solvents-q3c/ | 0.79 | % | — | NOT TESTED |
| Endotoxin | kinetic chromogenic LAL | 0.75 | EU/mg | ≤ 5.0 | PASS |
| Sterility | not ordered on this submission | not determined | — | no growth | NOT TESTED |
| Appearance | visual, diffuse light, black and white background | White cake, partial shrinkage from vial wall | — | white to off-white intact cake | FAIL |
| Reconstitution clarity | reconstituted per submitter procedure | Clear with a single visible fibre | — | clear, no visible particulates | FAIL |
| pH (reconstituted, 1 mg/mL) | potentiometric, two-point calibration | 4.55 | — | 2.5 – 8.0 | PASS |
| Retention time (observed) | RP-HPLC, 30 min gradient | 12.97 | min | 12.86 ± 0.30 (normalised) | PASS |
| Peak asymmetry (10 % height) | Ph. Eur. 2.2.46 | 1.21 | — | 0.80 – 1.50 | PASS |
| Plate count, main peak | N = 5.54 (t/w½)² | 39,481 | — | ≥ 20,000 | PASS |
| Resolution to nearest impurity | vs deamidated (+1 Da) | 0.90 | — | no index criterion | REPORTED |
Chromatogram and peak integration
The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.
| # | Peak | RT | Area (µV·s) | % area | Δ mass (Da) |
|---|---|---|---|---|---|
| 1 | CJC-1295 (no DAC) — main peak | 12.97 | 4,845,243 | 99.69 | — |
| 2 | des-Tyr1 (−163 Da) | 12.43 | 10,207 | 0.21 | -163.063 |
| 3 | truncated (1-24) | 11.81 | 3,402 | 0.07 | -570.291 |
| 4 | deamidated (+1 Da) | 12.73 | 972 | 0.02 | +0.984 |
| 5 | acetyl adduct (+42 Da) | 13.41 | 486 | 0.01 | +42.011 |
| Closure check — purity + Σ impurities | 100.00 | CLOSES | |||
Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.
Mass spectrum and identity
Theoretical monoisotopic mass 3365.7402 Da, computed from C152H252N44O42. All ppm figures on this site are against monoisotopic values — see why that matters.
| Charge | Theoretical m/z | Observed m/z | Δ m/z | Rel. abundance (%) |
|---|---|---|---|---|
| 5+ | 674.1553 | 674.1544 | -0.0009 | 8.0 |
| 4+ | 842.4423 | 842.4412 | -0.0011 | 51.3 |
| 3+ | 1122.9207 | 1122.9191 | -0.0016 | 100.0 |
| 2+ | 1683.8774 | 1683.8750 | -0.0024 | 58.6 |
Gravimetric mass balance
Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.
| Component | Determination | %w/w of cake |
|---|---|---|
| Water | Karl Fischer | 5.68 |
| Counter-ion (acetate) | ion chromatography | 3.98 |
| Residual solvent + inorganic residue | estimated | 0.79 |
| Total peptide content | by difference | 89.55 |
| Total | 100.00 CLOSES | |
Supplier certificate, as declared
The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.
| Figure | Supplier COA | This report | Index note |
|---|---|---|---|
| Purity (% area) | 99.57 | 99.69 | divergence -0.12 pp vs batch median |
| Total impurities (% area) | not stated | 0.31 | |
| Largest single impurity (% area) | not stated | 0.21 | |
| Water (%) | not stated | 5.68 | |
| Counter-ion (%) | not stated | 3.98 | |
| Peptide content (%w/w) | not stated | 89.55 | |
| Endotoxin (EU/mg) | not stated | 0.75 | |
| Method stated on certificate | YES | — | column, gradient and wavelength given |
Provenance and caveats
Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.
- Sample provenance
- Laboratory-retained
- Evidentiary weight
- Provenance documented, selection uncontrolled.
- Chain of custody
- Laboratory retained sample (−20 °C, 1 d since original receipt) → re-assay.
- Assay date
- 15 Feb 2026
- Submitted to the index
- 04 Mar 2026
- Laboratory
- Janoshik Analytical, Ostrava, Czechia
- Method basis
- 30 min gradient · high-resolution MS
- Verification status
- VERIFIED
Annotations 2
Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.
Related records
Same batch — lot HOMO-2512-D5035 n=1
This is the only report on this lot. One report is not a batch characterisation.
Cross-sections
| Report | Supplier | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-042942 | MKM | MKM-2603-V3346 | Janoshik | 2026-Q3 | 99.52 | 3.43 | — | Supplier-supplied | 0 | PASS |
| AX-2026-041599 | QSC | QSC-2606-V7416 | VendorInvestigate | 2026-Q3 | 97.96 | 3.52 | — | Buyer-sourced | 1 | FAIL |
| AX-2026-042784 | GGPeps | GGPE-2606-E1234 | Medutest | 2026-Q3 | 98.27 | 4.55 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042939 | MKM | MKM-2603-V3346 | PeptideMeter | 2026-Q3 | 99.44 | 3.39 | — | Buyer-sourced | 0 | PASS |
| AX-2026-041601 | QSC | QSC-2606-V7416 | Kestrel | 2026-Q3 | 98.33 | 4.10 | — | Buyer-sourced | 1 | MARGINAL |
| AX-2026-042945 | MKM | MKM-2603-V3346 | PeptideMeter | 2026-Q3 | 99.39 | 3.54 | — | Laboratory-retained | 0 | PASS |
| AX-2026-042786 | GGPeps | GGPE-2606-E1234 | Janoshik | 2026-Q3 | 98.22 | 3.77 | — | Buyer-sourced | 0 | PASS |
| AX-2026-041602 | QSC | QSC-2606-V7416 | VendorInvestigate | 2026-Q3 | 98.36 | 3.38 | 101.8 | Buyer-sourced | 1 | MARGINAL |
| Report | Compound | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-042437 | Retatrutide | HOMO-2605-V4718 | Nordanalyt | 2026-Q3 | 98.68 | 3.67 | 102.8 | Buyer-sourced | 0 | PASS |
| AX-2026-042424 | Semaglutide | HOMO-2604-X3806 | PeptideMeter | 2026-Q3 | 98.85 | 4.87 | 92.0 | Buyer-sourced | 0 | PASS |
| AX-2026-042503 | IGF-1 LR3 | HOMO-2607-P5131 | Janoshik | 2026-Q3 | 99.36 | 5.99 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042492 | SS-31 (Elamipretide) | HOMO-2604-D5484 | Medutest | 2026-Q3 | 99.93 | 2.40 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042491 | SS-31 (Elamipretide) | HOMO-2604-D5484 | Kestrel | 2026-Q3 | 99.93 | 3.24 | — | Supplier-supplied | 0 | PASS |
| AX-2026-042473 | LL-37 | HOMO-2602-G5165 | Janoshik | 2026-Q3 | 99.01 | 5.00 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042441 | Retatrutide | HOMO-2605-V4718 | Medutest | 2026-Q3 | 98.93 | 4.22 | — | Buyer-sourced | 0 | PASS |
| AX-2026-042474 | LL-37 | HOMO-2602-G5165 | Janoshik | 2026-Q3 | 99.18 | 5.44 | — | Buyer-sourced | 0 | PASS |